What this is
- This research investigates the potential causal relationship between various sleep phenotypes and the risk of ().
- Using a two-sample approach, genetic variants associated with sleep traits were analyzed to determine their impact on risk.
- The study found no evidence supporting a causal link between sleep phenotypes and the risk of developing .
Essence
- Genetically predicted sleep phenotypes do not causally affect the risk of (). This conclusion is based on a comprehensive analysis using methods.
Key takeaways
- No causal association exists between sleep phenotypes and risk. This includes traits such as daytime napping, insomnia, and obstructive sleep apnea.
- The study utilized genetic variants as instrumental variables, enhancing the reliability of the findings by reducing biases associated with observational studies.
- The lack of evidence for a causal relationship contrasts with some previous observational studies, suggesting that confounding factors may have influenced those earlier findings.
Caveats
- The study's findings may not be generalizable to non-European populations, as the data primarily included individuals of European ancestry.
- Self-reported sleep phenotype data could introduce exposure misclassification, potentially biasing the results.
- Although using genetic data reduces confounding, the possibility of overlap between exposure and outcome cohorts could still lead to biased results.
Definitions
- Mendelian randomization: An epidemiological method using genetic variants as instrumental variables to assess causal relationships between exposures and outcomes.
- Proliferative diabetic retinopathy (PDR): The advanced stage of diabetic retinopathy characterized by retinal neovascularization and a leading cause of vision loss.
AI simplified
Introduction
Diabetic retinopathy (DR) is the most common microvascular complication of diabetes and the leading cause of vision loss and blindness globally, with an overwhelming 103.12 million people with DR in 2020, which is envisaged to rise to 160.50 million by 20451,2. DR is classified into two main clinical stages: non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR)3.
The pathogenesis of DR still needs to be better understood. Previous studies showed that retinal microvascular damage leading to vascular leakage and ischemia-induced retinal neovascularization plays an essential role in DR pathogenesis4,5. Hypertension, obesity, blood glucose level, glycated hemoglobin (Hb)A1c, hyperlipidemia, dietary style, exercise, and smoking are also involved in its development6,7. In addition, growing epidemiological evidence suggests that sleep disorders are becoming emerging risk factors DR8.
For example, obstructive sleep apnea (OSA), the most common type of sleep disorder, is characterized by repeated apneas and hypopneas during sleep, leading to hypoxia and hypercapnia, where, OSA was reported to be associated with an increased DR risk9β11. Similarly, both short (β€ 5 h/day) and long (β₯ 9 h/day) sleep durations were also associated with an increased risk of DR in men12. However, studies investigating the role of OSA in DR have yielded conflicting results, where some studies studies even showed no association between OSA and DR13,14. Besides, considering the influence of selection biases, residual confounding, and reverse causality in observational studies, the causal effect between sleep disorders and the risk of DR is unclear.
Furthermore, the role of other sleep phenotypes such as daytime napping, sleepiness, chronotype, morning person, snoring, insomnia, sleep duration, short sleep duration, and long sleep duration in DR has yet to be extensively investigated. Revealing the causality of differential sleep phenotypes on DR might provide novel insights into the pathogenesis of diseases and devise future intervention studies.
Mendelian randomization (MR) is an emerging epidemiological method that uses genetic variants as instrumental variables to evaluate the causal relationship between exposures and outcomes and could reduce biases, residual confounding, and reverse causality15.
In the present study, to investigate the probable existence of a causal association between sleep phenotypes and PDR, a two-sample MR was performed to evaluate the associations between genetically predicted sleep phenotypes and PDR risk.
Methods
MR study design
A two-sample MR method was designed to estimate the magnitude of a causal effect of sleep phenotypes on PDR by using genetic variants as instrumental variables16. The overview of the study design is displayed in Fig. 1.
The overview of the MR study design. MR study is based on three main assumptions. Assumption 1: The genetic variants selected as instrumental variables should be associated with the risk factor. Assumption 2: Genetic variants used as instrumental variables should not be associated with known confounding factors. Assumption 3: The used genetic variants as instrumental variables should influence the risk of the outcome only via exposure.
Data for exposure
The summary-level data used in the study were obtained from publicly available GWASs of European ancestry (Table 1). The GWAS data on self-reported daytime napping, and sleepiness, chronotype, morning person, insomnia, sleep duration (7β9 h/day), short sleep duration (< 7 h/day), and long sleep duration (> 9 h/day) were download from the Sleep Disorder Knowledge Portal website (https://sleep.hugeamp.org/datasets.html)β17β21. The GWAS data on obstructive sleep apnea and snoring were derived from FinnGen (Risteys R9)22, and MRC Integrative Epidemiology Unit (IEU) (GWAS ID : ebi-a-GCST009761), respectively23,24.
| Exposure and outcome | Consortium | Category | Cases | Controls | Total | Used SNPs | VEP | F statistic | PMID | DOI/URL |
|---|---|---|---|---|---|---|---|---|---|---|
| Chronotype | UK Biobank | CV | 449,734 | β | 449,734 | 122 | 1.264 | 46.591 (28.834β209.387) | 3069 6823 | https://personal.broadinstitute.org/ryank/sleepdurationsumstats.txt.zip |
| Daytime napping | UK Biobank | DV | 196,895 | 255,738 | 452,633 | 77 | 0.788 | 46.307 (29.852β217.432) | 3356 8662 | https://personal.broadinstitute.org/ryank/Saxena_fullUKBB_Daytimenapping_summary_stats.zip |
| Daytime sleepiness | UK Biobank | DV | 104,786 | 347,285 | 452,071 | 25 | 0.233 | 42.118 (30.105β117.438) | 3140 9809 | https://personal.broadinstitute.org/ryank/Saxena.fullUKBB.DaytimeSleepiness.sumstats.zip |
| Insomnia | UK Biobank | DV | 108,357 | 345,022 | 453,379 | 28 | 0.265 | 42.84 (29.241β181.158) | 3080 4566 | https://personal.broadinstitute.org/ryank/Saxena_fullUKBB_Insomnia_summary_stats.zip |
| Long sleep duration | UK Biobank | DV | 34,184 | 305,742 | 339,926 | 6 | 0.055 | 41.135 (29.889β52.982) | 3084 6698 | https://personal.broadinstitute.org/ryank/longsumstats.txt.zip |
| Morning person | UK Biobank | DV | 252,287 | 150,908 | 403,195 | 99 | 1.099 | 44.758 (29.019β168.521) | 3069 6823 | https://personal.broadinstitute.org/ryank/morning_person_BOLT.output_HRC.only_plus.metrics_maf0.001_hwep1em12_info0.3_logORs.txt.gz |
| Short sleep duration | UK Biobank | DV | 106,192 | 305,742 | 411,934 | 16 | 0.137 | 38.324 (29.901β77.041) | 3084 6698 | https://personal.broadinstitute.org/ryank/shortsumstats.txt.zip |
| Obstructive sleep apnea | FinnGen | DV | 16,761 | 201,194 | 217,955 | 12 | 0.11 | 34.478 (30.085β42.202) | 3324 3845 | _SLEEPAPNO/ https://gwas.mrcieu.ac.uk/datasets/finn-b-G6 |
| Sleep duration | UK Biobank | CV | 446,118 | β | 446,118 | 47 | 0.429 | 40.734 (30.214β220.873) | 3084 6698 | https://personal.broadinstitute.org/ryank/sleepdurationsumstats.txt.zip |
| Snoring | UK Biobank | DV | 151,836 | 255,230 | 407,066 | 20 | 0.204 | 41.497 (29.898β74.508) | 3206 260 | https://gwas.mrcieu.ac.uk/files/ebi-a-GCST009761/ebi-a-GCST009761.vcf.gz |
| PDR | FinnGen | DV | 9,511 | 362,581 | 372,092 | 6 | 0.122 | 75.672 (38.742β175.766) | 3665 3562 | https://storage.googleapis.com/finngen-public-data-r9/summary_stats/finngen_R9_DM_RETINA_PROLIF.gz |
Instrumental variable selection
Single-nucleotide polymorphisms (SNPs) associated with sleep phenotypes were selected as instrumental variables at the genome-wide significance threshold (P < 5 Γ 10β8). To mitigate against co-linearity between SNPs, linkage disequilibrium (LD) analysis was performed to select independent SNPs with r2 < 0.001 and the clumping window of 10, 000 kb. Besides, proxy SNPs were also excluded from follow-up analysis. To avoid the potential effects of weak instrument bias, the strength of the genetic instrument was evaluated by F-statistics, and variance was explained (R2)25,26. The values of F statistic > 10 were considered robust MR instruments. Moreover, PhenoScanner (http://www.phenoscanner.medschl.cam.ac.uk/β) was used to evaluate the association of instrumental variables with confounding or risk factors for outcomes. The statistical power calculations for the MR analysis was performed using an online tool at http://cnsgenomics.com/shiny/mRnd/β27.
Data for outcome
GWAS summary data on PDR from FinnGen comprised 9511 cases and 362 581 controls (Table 1)22. The FinnGen study is a large personalized medicine project covering 500,000 Finnish biobank participants, and aims to provide the evidence of genomic effect on human health. The overall statistical analysis of the FinnGen study have already been published22. PDR, characterized by the progression of retinal neovascularization, is defined as the most advanced stage of diabetic eye disease in ICD-10 (code: H36.03*). To further assess the robustness of PDR GWAS, the PDR GWAS data were re-analyzed in our study. More detailed demographic characteristics of the participants of the PDR GWAS data can be obtained at https://r9.risteys.finngen.fi/endpoints/DM_RETINA_PROLIF#dialog-view-original-rulesβ.
Validation cohorts
To validate the reliability of the MR results in the FinnGen cohort, the GWAS data of insomnia and sleep duration in the UK Biobank subjects were retrieved from the IEU-OpenGWAS project (https://gwas.mrcieu.ac.uk/datasets/ukb-b-4424/β, and https://gwas.mrcieu.ac.uk/datasets/ukb-b-3957/β ).
Statistical analysis
A two-sample MR method was employed to evaluate the causal effects of sleep phenotypes on PDR. Results are presented as odds ratios (ORs) and 95% confidence intervals (CIs). IVW MR analysis with a randomβeffects model was applied as the primary MR analysis to estimate the causal association between the exposure and the outcome28. However, the IVW method is sensitive to invalid instrumental variables and pleiotropy29. Moreover, MR Egger regression, weighted median, simple mode, and weighted mode methods were employed as complementary analysis to test the consistency of causal estimates. The weighted median method provides consistent estimates, although half of the genetic variants are invalid instrumental variables29. The MR-Egger regression was applied to detect and adjust for pleiotropy, but the statistical power was low30. Bonferroni correction was used to adjust for multiple tests involving 10 sleep phenotypes. Statistical significance was defined as P < 0.005 (significance level 0.05/10 MR tests) for all analysis.
Sensitivity analysis
To assess the potential violation of the MR assumptions, a series of MR sensitivity analysis was performed to test the stability and reliability of the results. Cochran Q test and the I2 statistic were used to evaluate the heterogeneity. A fixed-effects model was used in case of significant heterogeneity; otherwise, a random-effects model was used31. The MR-Egger regression method and the intercept test were performed to evaluate horizontal pleiotropy. Besides, the MR pleiotropy residual sum and outlier (MR-PRESSO) method was also applied to test for possible bias from horizontal pleiotropy and outlier variants removal32. A leave-one-out analysis was utilized for further sensitivity analysis. The MR Steiger test of directionality was performed to test the causal direction between sleep phenotypes and the PDR outcomes and remove SNPs that have a more significant association with the outcome than sleep phenotypes33.
Linkage disequilibrium score regression (LDSC)
LDSC was used to estimate the genetic correlations between sleep phenotypes and PDR outcomes34.
Colocalization analysis
Colocalization analysis, a Bayesian-based method, provides five posterior probabilities for these hypotheses (PPH0: no causal variants for either trait; PPH1: a causal variant for trait 1; PPH2: a causal variant for trait 2; PPH3: two different causal variants for trait 1 and trait 2; and PPH4: a shared causal variant between two traits)35. Colocalization analysis was performed to examine whether sleep phenotypes and PDR share a common causal variant in a given region. For each of these sleep phenotypes and PDR pairs, the genomic region extending 1000 kb on both sides of the lead sleep phenotypes variant was used, and PPH4 > 75% was considered to have strong colocalization evidence.
Reverse MR analysis
To further investigate whether there is genetic evidence for a reverse causal effect of PDR on sleep phenotypes, a bi-directional MR analysis was performed with PDR as exposure and sleep phenotypes as outcomes.
Statistical analysis and analysis software
This MR study followed the guidelines for strengthening the reporting of observational studies in epidemiologyβMR (STROBE-MR)36. Statistical analyses were performed in R (version 4.1.2) Software, and MR analysis was performed using the TwoSampleMR package, and MR-PRESSO analysis was performed using the MRPRESSO package32,37. Colocalization analysis was used the Coloc package35.
Ethical approval and consent to participate
All participating studies of GWAS have obtained approval from relevant institutional review boards, and written informed consent was received from all subjects. Summary-level data in our study are publicly available. The Medical Ethics Committee of The First Affiliated Hospital of Henan University of Science and Technology ruled that no formal ethics approval was required for this study.
Results
Genetic instruments
In the present study, 122/77/25/28/6/99/16/12/47/20 SNPs were selected as genetic instruments for sleep phenotypes (Chronotype/Daytime napping/Daytime sleepiness/Insomnia/Long sleep duration/Morning person/Short sleep duration/Obstructive sleep apnea/Sleep duration/Snoring). The F statistics for all genetic instruments were > 10 (Table 1). Summary statistics data for the SNPsβexposure associations are presented in Supplementary Table 1. The six locus polymorphisms are significantly associated with PDR (P < 5 Γ 10β8) (Supplementary Table 2). Manhattan and QQ plots are shown in Supplementary Fig. 1A and B. Power analysis indicated all MR analysis were sufficiently powered (Supplementary Table 3).
MR analysis of sleep phenotypes on PDR risks
Two-sample MR analysis was initially performed to evaluate the causal effect of sleep phenotypes on PDR. Based on the IVW analysis results before Bonferroni correction, genetic predisposition to snoring was associated with increased risk of PDR (OR = 4.087 (95% CI 1.326β12.595), P = 0.014). In contrast, genetically predicted chronotype(OR = 0.890, 95% CI 0.761β1.040, P = 0.143), daytime napping (OR = 1.104, 95% CI 0.677β1.802, P = 0.691), daytime sleepiness (OR = 1.407, 95% CI 0.554β3.569, P = 0.473), insomnia (OR = 1.499, 95% CI 0.828β2.716, P = 0.181), long sleep duration (OR = 0.502, 95% CI 0.021β12.032, P = 0.671), morning person (OR = 0.918, 95% CI 0.826β1.020, P = 0.113), short sleep duration (OR = 1.545, 95% CI 0.415β5.752, P = 0.517), obstructive sleep apnea (OR = 1.206, 95% CI 0.971β1.498, P = 0.091), sleep duration (OR = 0.805, 95% CI 0.570β1.13, P = 0.216) were not causally associated with PDR risk. However, no causal relationship existed between genetically predicted sleep phenotypes and PDR after Bonferroni correction (Fig. 2).
The causal effect of genetically predicted sleep phenotypes on the risk of PDR.
Sensitivity analysis
According to Cochranβs Q test of heterogeneity using the IVW method, there was evidence of heterogeneity among individual SNP effect estimates in daytime napping on PDR (Q = 107.023, I2 = 29%, P = 0.011, Table 2). Therefore, a fixed-effects IVW model would be implemented. Similarly, there was no causal association between genetically predicted daytime napping and PDR (OR = 1.104, 95% CI 0.731β1.668, P = 0.638). Moreover, no evidence for horizontal pleiotropy was observed using the MR-Egger regression method (P > 0.05, Table 2). Additionally, the MR-PRESSO outlier test detected potential outliers, and re-analysis was carried out after removing outliers from genetic instruments. Furthermore, a leave-one-out analysis was also performed, and the results are presented in Supplementary Fig. 2.
| Exposure | Heterogeneity | Horizontal pleiotropy | MR PRESSO global testvalueP | ||||
|---|---|---|---|---|---|---|---|
| Q | valueP | I2 | Intercept | Se | valueP | ||
| Chronotype | 146.419 | 0.058 | 0.174 | 0.004 | 0.005 | 0.449 | 0.059 |
| Daytime napping | 107.023 | 0.011 | 0.29 | 0.007 | 0.009 | 0.452 | 0.014 |
| Daytime Sleepiness | 25.709 | 0.368 | 0.066 | 0.006 | 0.017 | 0.714 | 0.345 |
| Insomnia | 24.956 | 0.577 | ββ0.082 | ββ0.014 | 0.009 | 0.118 | 0.561 |
| Long sleep duration | 5.049 | 0.41 | 0.01 | 0.017 | 0.035 | 0.644 | 0.53 |
| Morning person | 117.045 | 0.092 | 0.163 | 0.005 | 0.006 | 0.371 | 0.095 |
| Short sleep duration | 16.126 | 0.374 | 0.07 | ββ0.009 | 0.024 | 0.719 | 0.376 |
| Obstructive sleep apnea | 15.314 | 0.169 | 0.282 | 0.016 | 0.023 | 0.497 | 0.186 |
| Sleep duration | 60.779 | 0.071 | 0.243 | ββ0.004 | 0.011 | 0.71 | 0.076 |
| Snoring | 25.424 | 0.147 | 0.253 | ββ0.033 | 0.021 | 0.134 | 0.177 |
Direction validation and confounders
Steiger direction test was performed to examine whether there was reverse causality between sleep phenotypes and PDR, where the results did not support the existence of reverse causal effects between the two. Some SNPs were associated with the known confounders (body mass index, glucose, diabetes, alcohol, smoking, cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein, blood pressure, insulin, and obesity), which were excluded from further analysis.
Results of genetic correlation analysis
The LDSC analysis results do not indicate any evidence for a genetic correlation between sleep phenotypes and PDR (Chronotype: rg = 0.0132, se = 0.0538, P = 0.8068; Daytime napping: rg = 0.0460, se = 0.0568, P = 0.4172; Daytime sleepiness: rg = 0.1022, se = 0.0601, P = 0.089; Insomnia: rg = 0.0789, se = 0.0555, P = 0.1551; Long sleep duration: rg = β 0.0003, se = 0.0817, P = 0.9971; Morning person: rg = 0.0115, se = 0.0564, P = 0.8390; Short sleep duration: rg = 0.0905, se = 0.0637, P = 0.1557; Obstructive sleep apnea: rg = 0.1387, se = 0.0697, P = 0.0465; Sleep duration: rg = β 0.0578, se = 0.0629, P = 0.3576; Snoring: rg = 0.0482, se = 0.0578, P = 0.4045) (Table 3).
| Exposure | Outcome | rg | rg_se | rg_p |
|---|---|---|---|---|
| Chronotype | Proliferative diabetic retinopathy | 0.013 | 0.054 | 0.807 |
| Daytime napping | Proliferative diabetic retinopathy | 0.046 | 0.057 | 0.417 |
| Daytime sleepiness | Proliferative diabetic retinopathy | 0.102 | 0.06 | 0.089 |
| Insomnia | Proliferative diabetic retinopathy | 0.079 | 0.056 | 0.155 |
| Long sleep | Proliferative diabetic retinopathy | 0 | 0.082 | 0.997 |
| Morning person | Proliferative diabetic retinopathy | 0.012 | 0.056 | 0.839 |
| Short sleep | Proliferative diabetic retinopathy | 0.091 | 0.064 | 0.156 |
| Sleep apnoea | Proliferative diabetic retinopathy | 0.139 | 0.07 | 0.047 |
| Sleep duration | Proliferative diabetic retinopathy | ββ0.058 | 0.063 | 0.358 |
| Snoring | Proliferative diabetic retinopathy | 0.048 | 0.058 | 0.405 |
Results of genetic colocalization analysis
The colocalization analysis results suggested that sleep phenotypes and PDR were unlikely to share a causal variant within the same locus. (Chronotype: PPH4 = 2%; Daytime napping: PPH4 = 4%; Daytime Sleepiness: PPH4 = 3%; Insomnia: PPH4 = 4%; Long sleep duration: PPH4 = 1%; Morning person: PPH4 = 2%; Short sleep duration: PPH4 = 1%; Obstructive sleep apnea: PPH4 = 1%; Sleep duration: PPH4 = 1%; Snoring: PPH4 = 40%) (Table 4 and Fig. 3).
Genetic colocalization analysis between sleep phenotypes and PDR.
| Exposure | PP.H0.abf | PP.H1.abf | PP.H2.abf | PP.H3.abf | PP.H4.abf |
|---|---|---|---|---|---|
| Chronotype | 1.78e-41 | 0.39 | 2.67e-41 | 0.59 | 0.02 |
| Daytime napping | 1.14e-42 | 0.72 | 3.91e-43 | 0.25 | 0.04 |
| Daytime sleepiness | 3.72e-20 | 0.71 | 1.37e-20 | 0.26 | 0.03 |
| Insomnia | 2.16e-34 | 0.71 | 7.62e-35 | 0.25 | 0.04 |
| Long sleep duration | 0.00000102 | 0.83 | 1.95e-7 | 0.16 | 0.01 |
| Morning person | 9.65e-33 | 0.39 | 1.45e-32 | 0.59 | 0.02 |
| Short sleep duration | 6.82e-12 | 0.84 | 1.29e-12 | 0.16 | 0.01 |
| Obstructive sleep apnea | 3.74e-21 | 0.57 | 2.81e-21 | 0.43 | 0.01 |
| Sleep duration | 1.65e-43 | 0.83 | 3.12e-44 | 0.16 | 0.01 |
| Snoring | 2.45e-12 | 0.28 | 2.78e-12 | 0.32 | 0.4 |
Results of MR analysis in the UK subjects
We replicated the MR analysis on the UK Biobank cohort. Genetically predicted insomnia (OR = 1.304, 95% CI 0.810β2.099, P = 0.275), sleep duration (OR = 0.846, 95% CI 0.581β1.231, P = 0.382) were not causally associated with PDR risk based on IVW analysis (Supplementary Table 4).
Results of reverse MR analysis
The results of an inverse MR analysis showed no causal association between PDR and sleep phenotypes (Fig. 4).
The causal effect of genetically predicted PDR on the risk of sleep phenotypes.
Discussion
The current study explored the bidirectional causal association between sleep phenotypes and PDR, and SNP-based genetic correlation was evaluated. Results suggested no evidence of causal associations of daytime napping, daytime sleepiness, chronotype, morning person, insomnia, sleep duration, short, and long sleep duration, obstructive sleep apnea, snoring, and PDR. Additionally, the sensitivity analysis revealed cemented the robustness and reliability of the results. The genetic correlation analysis also did not provide strong evidence supporting a causal association between sleep phenotypes and PDR, further supported by the lack of sharing a common causal variant in colocalization analysis results. This is the first study to evaluate the effects of genetically predicted sleep phenotypes and PDR using MR analysis.
Moreover, this study did not provide any evidence regarding genetically predicted sleep phenotypes playing a role in the increased PDR risk, which was contrary to several previous observational studies. Tan et al.β study reported that short and long sleep duration increased the risk of DR compared to normal sleep duration38. Similarly, a longitudinal study on 230 recruited diabetes type 2 patients found that obstructive sleep apnea was an independent risk factor for DR39. Besides, a retrospective observational study also identified severe obstructive sleep apnea associated with a higher prevalence of DR, proliferative DR, and diabetic macular edema (DME)40. Daytime sleepiness was also reported to be associated with vision-threatening DR, and insomnia as well to be associated with increased susceptibility to DR, vision-threatening DR, and DME38,41. In addition, An observational study found that OSA diagnosed by questionnaires and diagnosis codes was not significantly associated with DR, while OSA diagnosed by objective sleep assessments was significantly associated with DR42.
However, several controversial results also have been reported by relevant studies. Raman et al. confirmed that short and long sleep duration are not risk factors for DR in women and men43. The prospective caseβcontrol study and meta-analysis results also suggested that obstructive sleep apnea was not associated with DR44,45.
The effect of snoring, daytime napping, chronotype, and morning person on PDR has been negligibly studied. The novelty of our work lies for the first time in reporting no causal effects of these sleep phenotypes on PDR.
Furthermore, our results also conflict with previous observational studies regarding the relationship between sleep phenotypes and PDR. However, most previous studies were prospective or retrospective cohorts and crossβsectional studies, given the nature of the observational, selection bias and unmeasured confounders cannot be excluded and causality cannot be determined. Mendelian randomization could reduce the influence of unknown or unmeasured confounders. Confounding factors may explain the findings between the present study and previous observational studies. For example, the role of the gut-retina" axis in DR has increasingly been recognized46. Sleep disorders can affect the composition of the intestinal microbiota47. A recent MR study has demonstrated that gut microbiota positively affects DR48. Sleep phenotypes might result in DR by modulating the intestinal microbiota49. In addition, inflammation may be a potential confounder factor for previous observational studies since it plays a fundamental role in DR pathogenesis by disrupting the retinal blood barrier50. Sleep phenotypes might indirectly participate in the prevalence of DR by modulating insulin sensitivity and affecting blood glucose levels51. In addition, Sleep rhythm disorders could lead to chronic metabolic disorders of melatonin. The melatonin levels of the DR group were significantly lower than those of the no-DR group42. Melatonin could significantly reduce the inflammatory markers levels of tumor necrosis factor-Ξ±, interleukin-1Ξ², and inducible nitric oxide synthase (iNOS) in DR52. Sleep phenotypes may indirectly affect the occurrence and development of DR by regulating the level of melatonin. Our results further emphasize the need to explore the potential causal association between sleep phenotypes and PDR.
Our results were robust and reliable, along with detecting heterogeneity and horizontal pleiotropy results via sensitivity analysis. In addition, leave-one-out analysis was used to validate the effect of a single SNP on the causal relationship between sleep phenotypes and PDR. MR-PRESSO method was performed to recognize and remove outlying SNPs that might cause horizontal pleiotropy effects. The sample size was sufficiently large to provide enough power for the statistical analysis in this study. Our results were unlikely to suffer weak instrument bias because the F-statistics for the instrumental variables were > 10. Moreover, the PhenoScanner database was also used to detect potential pleiotropic SNPs. Body mass index, glucose, diabetes, alcohol, smoking, cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein, blood pressure, insulin, and obesity were considered as potential confounders in this study53,54.
This study had several strengths. First, gene variants were used as instrumental variables to infer causal relationships between sleep phenotypes and PDR, which reduced the effect of confounders and reverse causation. Second, the impact of snoring, daytime napping, chronotype, and morning person on PDR risk was reported for the first time in this stud. Third, SNPs as instrumental variables were derived from large-scale GWASs, providing reliable estimates for the causal relationships between sleep phenotypes and PDR and less vulnerability to weak instrumental bias. We further validated our results using genetic correlation analysis and colocalization analysis.
However, our study also had several limitations. First, Sleep phenotypes in different human populations may have different genetic underpinnings. In a recent genome-wide association study (GWAS) meta-analysis for sleep duration, Takeshi et al.55 reported that PAX8 and VRK2 gene polymorphisms were not associated with sleep duration in Japanese individuals but were associated with sleep duration in the UK population. Our study was mainly based on Europeans, indicating that results may not be generalizable to other ethnic groups, necessitating validation in different populations. Second, most of the GWAS data on the sleep phenotypes were derived from self-reported questionnaire results. This may lead to exposure misclassification and potential bias. Thus, further prospective sleep evaluation using objective sleep parameters is warranted to understand better the relationship between sleep phenotypes and the risk of PDR. Finally. Although the samples of exposures and outcomes are from different cohorts, there is a potential overlap between exposures and outcomes, leading to the possibility of results bias.
Conclusion
Our study did not support the causal effect between sleep phenotypes and PDR. Further longitudinal studies are warranted to validate the findings. In addition, the impact effect of sleep phenotypes diagnosed by clinicians and PDR needs to be investigated in the future.
Supplementary Information
Acknowledgements
We would like to thank the IEU Open GWAS database, FinnGen, and the Sleep Disorder Knowledge Portal project publicly available.
Abbreviations
Author contributions
J.W. and H.L., designed the study. H.L., X.Z., and L.L. collected and analyzed data. H.L. and L.L. conducted the literature search. H.L. wrote the first draft of the paper. J.W. and L.L. supervised the study. All authors gave consent for the publication.
Data availability
All data generated or analyzed during this study are included in this published article. The raw data can be obtained from the IEU Open GWAS database (https://gwas.mrcieu.ac.uk/β) and the Sleep Disorder Knowledge Portal project (https://sleep.hugeamp.org/datasets.htmlβ).
Competing interests
The authors declare no competing interests.
Footnotes
Supplementary Information
The online version contains supplementary material available at 10.1038/s41598-024-60446-3.
References
Associated Data
Supplementary Materials
Data Availability Statement
All data generated or analyzed during this study are included in this published article. The raw data can be obtained from the IEU Open GWAS database (https://gwas.mrcieu.ac.uk/β) and the Sleep Disorder Knowledge Portal project (https://sleep.hugeamp.org/datasets.htmlβ).